摘要
过氧化物酶体增殖物激活受体γ辅激活因子1α(PGC-1α)是调节细胞能量代谢的重要的辅助活化因子,其在线粒体的生物合成、骨骼肌纤维类型转换、机体适应性产热、糖代谢以及脂代谢中发挥重要作用,同时还可以调节内皮细胞的稳态。PGC-1α在代谢性疾病、糖尿病肾病、心血管疾病以及肿瘤和神经性退行性疾病患者中的表达水平与正常人不同,其有可能成为以上疾病治疗的新靶点,为疾病的治疗提供新的途径,以期改善患者的生活质量。
Peroxisome proliferator receptor-γcoactivator 1α(PGC-1α)is an important auxiliary activator in regulating cell energy metabolism,which plays a key role in mitochondrial biogenesis,fiber-type switching in skeletal muscles and adaptive thermogenesis,glucose and lipid metabolism.Meanwhile,it also can regulate the endothelial homeostasis.The levels of PGC-1αof metabolic diseases,diabetic nephropathy,cardiovascular disease,tumor and neurodegenerative disease are different from those of the health persons,and it might be the action target of those diseases,and provide new treatment ways,so as to improve the quality of life of the patients.
作者
李琳琳
曹正宇
田野
LI Linlin;CAO Zhengyu;TIAN Ye(Department of Cardiology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《医学综述》
2018年第13期2532-2536,2542,共6页
Medical Recapitulate
基金
国家自然科学基金(81727809)
